Evidence map›Paper›PMID 28978716›Full record

ArticlePediatrics2017

Immunization, Antibiotic Use, and Pneumococcal Colonization Over a 15-Year Period.

Grace M Lee, Ken Kleinman, Stephen Pelton, Marc Lipsitch, Susan S Huang, Matt Lakoma, Maya Dutta-Linn, Melisa Rett, William P Hanage, Jonathan A Finkelstein

Abstract read
In one paragraph

Article in Pediatrics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Article
  3. Colonization dynamics ofInfection and immunity · 2025
    Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Association between nasopharyngeal colonization with multiple pneumococcal serotypes and total pneumococcal colonization density in young Peruvian children.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2023
    Article
  9. Article
  10. Variability in discharge opioid prescribing practices for children: a historical cohort study.Canadian journal of anaesthesia = Journal canadien d'anesthesie · 2022
    Article
  11. Dynamic changes in otopathogens colonizing the nasopharynx and causing acute otitis media in children after 13-valent (PCV13) pneumococcal conjugate vaccination during 2015-2019.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2022
    Article
  12. Article
  13. Experimental Human Pneumococcal Colonization in Older Adults Is Feasible and Safe, Not Immunogenic.American journal of respiratory and critical care medicine · 2021
    Article
  14. Article
  15. Article
  16. Article
  17. Panel 8: Vaccines and immunology.International journal of pediatric otorhinolaryngology · 2020
    Review
  18. Article
  19. [Austrian syndrome: A rare manifestation of invasive pneumococcal disease. A case report and bibliographic review].Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2019
    Review
  20. Microbiome as a tool and a target in the effort to address antimicrobial resistance.Proceedings of the National Academy of Sciences of the United States of America · 2018
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Grace M LeeCenter for Healthcare Research in Pediatrics, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts; grace.lee@childrens.harvard.edu.
Ken KleinmanDepartment of Biostatistics and Epidemiology, University of Massachusetts Amherst School of Public Health and Health Sciences, Amherst, Massachusetts.
Stephen PeltonDivision of Infectious Diseases, Boston Medical Center, Boston, Massachusetts.
Marc LipsitchCenter for Communicable Disease Dynamics, Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts; and.
Susan S HuangDivision of Infectious Diseases and Health Policy Research Institute, University of California, Irvine School of Medicine, Orange, California.
Matt LakomaCenter for Healthcare Research in Pediatrics, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts.
Maya Dutta-LinnCenter for Healthcare Research in Pediatrics, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts.
Melisa RettCenter for Healthcare Research in Pediatrics, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts.
William P HanageCenter for Communicable Disease Dynamics, Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts; and.
Jonathan A FinkelsteinCenter for Healthcare Research in Pediatrics, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts.

Funding

Post-PCV pneumococcal population genetics and resistanceR01AI066304 · NIAID · HARVARD PILGRIM HEALTH CARE, INC. · PI FINKELSTEIN, JONATHAN A · 2006 to 2014
$6.4M
NIAID NIH HHS R01 AI066304
6 · The paper itself

Abstract

backgroundRates of invasive pneumococcal disease have declined since widespread introduction of pneumococcal conjugate vaccines (PCVs) in the United States. We evaluated the impact of immunization status and recent antibiotic use on an individual child's risk of colonization.

methodsThis study extends previously reported data from children <7 years of age seen for well child or acute care visits in Massachusetts communities. Nasopharyngeal swabs were collected during 6 surveillance seasons from 2000 to 2014. Parent surveys and medical record reviews confirmed immunization status and recent antibiotic use. We estimated the proportions of children colonized with PCV7-included, additional PCV13-included, and non-PCV13 serotypes. Risk factors for colonization with additional PCV13-included and non-PCV13 serotypes were assessed by using generalized linear mixed models adjusted for clustering by community.

resultsAmong 6537 children, 19A emerged as the predominant serotype in 2004, with substantial reductions in 2014. Among non-PCV serotypes, 15B/C, 35B, 23B, 11A, and 23A were most common in 2014. We observed greater odds for both additional PCV13 and non-PCV13 colonization in younger children, those with more child care exposure, and those with a concomitant respiratory tract infection. Adjusted odds for additional PCV13 colonization was lower (odds ratio 0.48 [95% confidence interval 0.31-0.75]) among children up-to-date for PCV13 vaccines. Recent antibiotic use was associated with higher odds of additional PCV13 colonization but substantially lower odds of non-PCV13 colonization.

conclusionsDespite the success of pneumococcal vaccines in reducing colonization and disease due to targeted serotypes, ongoing community-based surveillance will be critical to evaluate the impact of interventions on pneumococcal colonization and disease.

Indexed as

Anti-Bacterial AgentsChildChild, PreschoolFemaleHeptavalent Pneumococcal Conjugate VaccineHumansImmunizationInfantMaleMassachusettsPneumococcal InfectionsPneumococcal VaccinesSerogroupStreptococcus pneumoniaeTime Factors13-valent pneumococcal vaccineAnti-Bacterial AgentsHeptavalent Pneumococcal Conjugate VaccinePneumococcal Vaccines

Identifiers

PMID28978716
PMCPMC5654389

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.